FDA submitted a proposed information collection to OMB for Paperwork Reduction Act review regarding formal hearing administrative procedures and practices.
HUD published regulatory waivers granted during the third quarter of 2025 (July 1–September 30) in compliance with the HUD Reform Act's quarterly Federal Register notice requirement.
Tell Bizmoon what your business does and we'll cut the Federal Register down to what actually matters.
Every rule is broken into specific to-dos with calendar dates.
We tell you which parts of your business each rule actually touches.
After healthcare come the capital-heavy sectors: trade, transportation, energy, and finance. If you operate in one of them, the volume of change is relentless.
HUD publishes regulatory waivers granted during the fourth quarter of 2025 (October 1 through December 31) as required by Section 106 of the HUD Reform Act.
HUD establishes FY 2026 Renewal Funding Inflation Factors averaging 2.337 percent to adjust Housing Choice Voucher program allocations for public housing agencies based on local Fair Market Rent changes.
CDC seeks public comment on a proposed Management Information System for Comprehensive Cancer Control Programs that will conduct annual key informant interviews and biennial surveys to monitor program outcomes.
CDC seeks public comment through [date] on the Expanding PrEP in Communities of Color (EPICC) data collection effort, which supports shared decision-making training and evaluation for preexposure prophylaxis providers serving diverse populations.
CDC seeks public comment on a data collection for mChoice, a research study testing tailored provider training and adherence support to improve PrEP uptake among young men who have sex with men in high-priority settings.
DEA issues temporary scheduling order placing 7-hydroxymitragynine above a specified threshold in Schedule I, subjecting manufacturers, distributors, importers, exporters, and researchers to Schedule I controlled substance regulations and penalties.
The Drug Enforcement Administration announces temporary scheduling of mitragynine pseudoindoxyl, MGM-15, and MGM-16 as Schedule I controlled substances, restricting manufacturing, distribution, possession, and research activities.
FDA corrects contact information for the Expedited Investigational New Drug Pilot Program docket, which solicits public input on shortening timelines from drug identification to first-in-human clinical trials.
No legal jargon. Read the impact in two sentences.
Email + dashboard pings the moment something changes.
